BYSI
HealthcareBeyondSpring Inc.
$1.51
$-0.10 (-6.21%)
Jan 5, 2026
Price History (1Y)
Analysis
BeyondSpring Inc. is a biotechnology company in the healthcare sector with a relatively small scale, employing 40 individuals and having a market capitalization of $62.09M. The company's financial health appears to be challenging, as indicated by its profitability metrics. The gross margin, operating margin, and profit margin are all at 0.0%, suggesting that BeyondSpring Inc. may not have achieved significant revenue or income in the given time period. However, the company has a substantial amount of cash on hand, totaling $12.62M, which could provide some financial flexibility. The valuation context for BeyondSpring Inc. is characterized by negative P/E and EV/EBITDA ratios (-3.21 and -8.30 respectively), indicating that the market's assessment of the company's performance may be unfavorable. The 52-week high and low prices were $3.44 and $0.98, respectively, with a beta of 0.55 suggesting a relatively stable stock price compared to the broader market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Visit website →Key Statistics
- Market Cap
- $62.09M
- P/E Ratio
- N/A
- 52-Week High
- $3.44
- 52-Week Low
- $0.98
- Avg Volume
- 267.01K
- Beta
- 0.55
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 40